Analysts forecast that Arcturus Therapeutics Ltd (NASDAQ:ARCT) will post sales of $4.01 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Arcturus Therapeutics’ earnings. The lowest sales estimate is $3.00 million and the highest is $4.57 million. Arcturus Therapeutics posted sales of $2.39 million during the same quarter last year, which suggests a positive year-over-year growth rate of 67.8%. The business is scheduled to report its next earnings results after the market closes on Thursday, August 15th.
According to Zacks, analysts expect that Arcturus Therapeutics will report full year sales of $14.24 million for the current year, with estimates ranging from $6.80 million to $18.75 million. For the next year, analysts forecast that the firm will report sales of $14.63 million, with estimates ranging from $10.00 million to $18.88 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Arcturus Therapeutics.
Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.15). The company had revenue of $4.35 million for the quarter, compared to analysts’ expectations of $3.47 million. Arcturus Therapeutics had a negative net margin of 124.59% and a negative return on equity of 132.46%.
Shares of NASDAQ ARCT traded up $0.37 during trading on Monday, reaching $10.46. 83,184 shares of the company traded hands, compared to its average volume of 119,157. The firm’s 50 day moving average price is $10.28. The company has a debt-to-equity ratio of 2.43, a current ratio of 2.51 and a quick ratio of 2.51. The stock has a market capitalization of $137.34 million, a PE ratio of -4.84 and a beta of 2.36. Arcturus Therapeutics has a 52-week low of $4.11 and a 52-week high of $15.50.
Institutional investors have recently added to or reduced their stakes in the company. Nikko Asset Management Americas Inc. bought a new stake in shares of Arcturus Therapeutics during the first quarter valued at approximately $438,000. ARK Investment Management LLC raised its position in shares of Arcturus Therapeutics by 13.7% during the first quarter. ARK Investment Management LLC now owns 927,144 shares of the biotechnology company’s stock valued at $6,332,000 after buying an additional 111,968 shares during the last quarter. Creative Planning bought a new stake in shares of Arcturus Therapeutics during the first quarter valued at approximately $416,000. JPMorgan Chase & Co. bought a new stake in shares of Arcturus Therapeutics during the second quarter valued at approximately $128,000. Finally, Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Arcturus Therapeutics during the second quarter valued at approximately $1,227,000. Hedge funds and other institutional investors own 12.66% of the company’s stock.
About Arcturus Therapeutics
Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
Further Reading: Why do companies issue convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.